Lupus Research Alliance Applauds FDA’s Fast Track Designation to Develop Baricitinib for Lupus

NEW YORK, NY. December 14. The Lupus Research Alliance is pleased to share good news about a potential new treatment for systemic lupus erythematosus (SLE).  Yesterday, Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to baricitinib, which is being studied for the treatment of SLE. […] Read More